This site is intended for health professionals only
The Committee for Medicine Products for Human Use (CHMP) has refused, on re-examination of Allos Therapeutics Limited’s application, to recommend marketing authorisation for Folotyn (pralatrexate) for treatment of peripheral T-cell lymphoma.
This follows its adoption of a negative opinion on 19 January 2012, when it recommended refusal of marketing authorisation for Folotyn for peripheral T-cell lymphoma.
Folotyn contains the active substance pralatrexate, and it was intended to be available as a solution for infusion.
Folotyn was designated an ‘orphan medicine’, for use in rare diseases, 13 April 2007.